Advances in antifungal susceptibility testing of candida, 2010-2012

Current Fungal Infection Reports

Volumn 6, Issue 3, 2012, Pages 141-153

  Pfaller, Michael A ^a   Castanheira, Mariana ^b   Jones, Ronald N ^b  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Antifungal agents; Candida; CLSI; ECVs and Clinical Breakpoints

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; GLUCAN SYNTHASE; ITRACONAZOLE; MICAFUNGIN; MULTIDRUG RESISTANCE PROTEIN 1; POSACONAZOLE; STEROL 14ALPHA DEMETHYLASE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLAVISPORA LUSITANIAE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MANIPULATION; HUMAN; IN VITRO STUDY; INVASIVE CANDIDIASIS; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; OROPHARYNX CANDIDIASIS; OUTCOME ASSESSMENT; PICHIA ANOMALA; PICHIA GUILLIERMONDII; POINT MUTATION; REVIEW; WILD TYPE;

EID: 84869115052     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-012-0092-z     Document Type: Review

References (77)

1. CLSI. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts: Third edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
2. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST definitive document EDef 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398-405.
3. Arendrup MC, Garcia-Effron G, Lass-Florl C, et al. Echinocandin susceptibility testing of Candida species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother. 2010;54:426-439. A very comprehensive and useful investigation of several different methods to detect in vitro resistance to the echinocandins.
4. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol. 2010;48:1592-9.
5. Pfaller MA, Espinel-Ingroff A, Boyken L, et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) with the 24-h CLSI BMD method for fluconazole, posaconzole, and voriconazole susceptibility testing of Candida species using epidemiological cutoff values. J Clin Microbiol. 2011;49:845-850. An extensive comparison of the EUCAST and CLSI BMD methods for testing Candida versus azole antifungal agents demonstrating the harmonization of the methods.
6. Arendrup MC, Sulim S, Holm A, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol. 2011;49:3300-8.
7. Cuenca-Estrella M, Rodriguez-Tudela JL. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev Anti Infect Ther. 2010;8:267-76.
8. Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis. 2006;19:538-43.
9. Johnson EM. Issues in antifungal susceptibility testing. J Antimicrob Chemother. 2008;61 Suppl 1:i13-8.
10. Perkhofer S, Mrazek C, Hartl L, Lass-Florl C. In vitro susceptibility testing in fungi: What is its role in clinical practice? Curr Infect Dis Rep. 2010;12:401-8.
11. Pfaller MA. Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:S3-S13.
12. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982-9.
13. Rogers TR. Antifungal drug resistance: Limited data, dramatic impact? Int J Antimicrob Agents. 2006;27 Suppl 1:7-11.
14. Pfaller MA, Diekema D. Wild-type MIC distributions and epidemiological cutoff values for fluconazole and Candida: Time for new clinical breakpoints? Curr Fungal Infect Rep. 2010;4:168-74.
15. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 2010;48:52-6.
16. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol. 2011;49:630-7.
17. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J Clin Microbiol. 2011;49:3800-4.
18. Pfaller MA, Espinel-Ingroff A, Castanheira M, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol. 2012;50:2040-6. A comprehensive study to determine the ECVs for 3 older antifungal agents and 8 different species of Candida.
19. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updates. 2010;13:180-195. A description of the new CLSI species-specific clinical breakpoints for fluconazole and Candida.
20. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: Review of microbiologic, molecular, pharmaclodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol infect Dis. 2011;70:330-343. A description of the new CLSI species-specific clinical breakpoints for voriconazole and Candida.
21. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updates. 2011;14:164-176. A description of the new CLSI species-specific clinical breakpoints for the echinocandins and Candida.
22. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20:391-408.
23. Kahlmeter G, Brown DF, Goldstein FW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother. 2003;52:145-8.
24. Simjee S, Silley P, Werling HO, Bywater R. Potential confusion regarding the term 'resistance' in epidemiological surveys. J Antimicrob Chemother. 2008;61:228-9.
25. Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother. 2009;53:1628-9.
26. Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12:418-25.
27. Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2011;49:624-9.
28. Law D, Moore CB, Denning DW. Amphotericin B resistance testing of Candida spp.: A comparison of methods. J Antimicrob Chemother. 1997;40:109-12.
29. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother. 2006;50:1287-92.
30. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev. 2001;14:643-58.
31. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325-30.
32. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother. 1995;39:40-4.
33. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-9.
34. British Society for Mycopathology. Laboratory methods for flucytosine (5-fluorocytosine). Report of a Working Group of the British Society for Mycopathology. J Antimicrob Chemother. 1984;14:1-8.
35. CLSI. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
36. Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. Cladespecific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother. 2004;48:2223-7.
37. Hope WW, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother. 2004;48:4377-86.
38. Pujol C, Pfaller MA, Soll DR. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother. 2004;48:262-6.
39. Edlind TD, Katiyar SK. Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob Agents Chemother. 2010;54:4733-8.
40. Vandeputte P, Pineau L, Larcher G, et al. Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata. Mycopathologia. 2011;171:11-21. An excellent discussion of the mechanisms of resistance to flucytosine in C. glabrata.
41. McManus BA, Moran GP, Higgins JA, Sullivan DJ, Coleman DC. A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis. Antimicrob Agents Chemother. 2009;53: 4678-85.
42. Florent M, Noel T, Ruprich-Robert G, et al. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole crossresistance in clinical isolates of Candida lusitaniae. Antimicrob Agents Chemother. 2009;53:2982-90.
43. Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: Mechanisms epidemiology, and clinical significance. J Invasive Fungal Infect. 2007;1:74-92.
44. Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501-17.
45. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2:73-85.
46. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004;48:2124-31.
47. Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 1998;42:2932-7.
48. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994;18:240-2.
49. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1997;41:1482-7.
50. Marr KA, White TC, van Burik JA, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis. 1997;25:908-10.
51. Marr KA, Lyons CN, Rustad TR, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother. 1998;42:2584-9.
52. Mori T, Matsumura M, Kanamaru Y, et al. Myelofibrosis complicated by infection due to Candida albicans: Emergence of resistance to antifungal agents during therapy. Clin Infect Dis. 1997;25:1470-1.
53. Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother. 1997;41:196-9.
54. MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC, Sanglard D. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Chemother. 2010;54:1476-1483. A very useful demonstration of the impact of azole resistance mechanisms in C. albicans.
55. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998;11:382-402.
56. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997;24:235-47.
57. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
58. Perlin DS. Echinocandin-resistant Candida: Molecular methods and phenotypes. Curr Fungal Infect Reports. 2011;5:113-119. A very clear and complete discussion of the molecular aspects of echinocandin resistance in Candida.
59. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: Implications for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53:3690-9.
60. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: Implications for interpretive breakpoints. Antimicrob Agents Chemother. 2009;53:112-22.
61. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305-12.
62. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19:435-47.
63. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006;44:819-26.
64. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: Analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46: 2620-9.
65. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol. 2002;40:3841-4.
66. Cuenca-Estrella M, Lee-Yang W, Ciblak MA, et al. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother. 2002;46:3644-7.
67. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43:3884-9.
68. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (EDef. 7.1) and CLSI (M27-A2). J Clin Microbiol. 2007;45:109-11.
69. Romero M, Canton E, Peman J, Gobernado M. Study of in vitro activity of caspofungin on non-Candida albicans yeast strains determined by two methods: M27-A2 and EUCAST. Rev Esp Quimioter. 2004;17:257-62.
70. Pfaller MA, Boyken LB, Hollis RJ, et al. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: Results from a global Candida antifungal surveillance program. J Clin Microbiol. 2008;46:3585-90.
71. Cuenca-Estrella M, Gomez-Lopez A, Alastruey-Izquierdo A, et al. Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. J Clin Microbiol. 2010;48:1782-6.
72. Peterson JF, Pfaller MA, Diekema DJ, Rinaldi MG, Riebe KM, Ledeboer NA. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. J Clin Microbiol. 2011;49:1765-71.
73. Pfaller MA, Espinel-Ingroff A, Jones RN. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol. 2004;42:4577-80.
74. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol. 2007;45:3522-8.
75. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol. 2007;45:796-802.
76. Pfaller MA, Chaturvedi V, Diekema DJ, et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2008;46 :2155-9.
77. Posteraro B, Martucci R, La Sorda M, et al. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata. J Clin Microbiol. 2009;47:1927-30.